MapLight Therapeutics, Inc. MPLT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $53.68M-16.9% | $64.62M+139% | $27.09M+0.9% | $26.85M+35.7% | $19.79M-4.5% | ||
| $10.82M-42.3% | $18.75M+326% | $4.4M+15.3% | $3.82M+1.7% | $3.76M+82.0% | ||
| $64.5M-22.6% | $83.38M+165% | $31.5M+2.7% | $30.67M+30.3% | $23.54M+3.4% | ||
| -$64.5M+22.6% | -$83.38M-165% | -$31.5M-2.7% | -$30.67M-30.3% | -$23.54M-3.4% | ||
| $1.36M-64.4% | $3.83M+84.1% | $2.08M+27.6% | $1.63M+316% | $392K-74.7% | ||
| -$60.67M+23.7% | -$79.55M-170% | -$29.42M+1.4% | -$29.85M-33.6% | -$22.34M-5.2% | ||
| -$1.34— | —— | -$37.18— | —— | -$29.33-4.7% | ||
| -$64.34M+22.7% | -$83.24M-165% | -$31.4M-3.0% | -$30.49M-30.4% | -$23.38M-3.5% | ||
| -$64.5M+22.6% | -$83.38M-165% | -$31.5M-2.7% | -$30.67M-30.3% | -$23.54M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MapLight Therapeutics, Inc. profitable?
- MapLight Therapeutics, Inc. is not currently profitable: it reported a net loss of $199.5M over the trailing twelve months.
- What is MapLight Therapeutics, Inc. 's earnings per share?
- MapLight Therapeutics, Inc. 's diluted EPS over the trailing twelve months is $-95.86.
- Where does MapLight Therapeutics, Inc. 's income statement data come from?
- Every line is extracted from MapLight Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.